^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

    Excerpt:
    Consistent with overall survival, patients who had a high EGFR gene copy number seemed to achieve better objective response rate and TTF than those with a low EGFR gene copy number (Table 3).....With gefitinib, longer median survival was seen in patients with a high versus low EGFR gene copy number (8.3 v 4.3 months, respectively; HR, 0.78; 95% CI, 0.54 to 1.13).
    DOI:
    10.1200/JCO.2006.06.3958
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Excerpt:
    ...Response duration, progression-free survival, and overall survival`Safety`Ability of various somatic activating mutations in the TK region of the epidermal growth factor receptor (EGFR) gene to predict response and toxicity`Molecular profile`Significance of germline polymorphisms of the EGFR gene, somatic amplification of the EGFR gene, and other molecular factors for their association with clinical outcome parameters...
    Trial ID:
    NCT00411047
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

    Excerpt:
    Increased EGFR gene copy number was associated with increased OS (HR = 0.77; 95% CI 0.66–0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46–0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28–0.91; P = 0.02)….Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes.
    DOI:
    10.1093/annonc/mdq432
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines

    Excerpt:
    We investigated the relationship between mutations, CNGs and response to TKIs in a large panel of NSCLC cell lines….IC50 values for the TKIs gefitinib (Iressa) and erlotinib (Tarceva) were determined by MTS assay….Multivariate analyses led to the following results: 1. mEGFR and gEGFR and gHER2 were independent factors related to gefitinib sensitivity, in descending order of importance....
    DOI:
    10.1371/journal.pone.0004576